



**Mark Kazmierczak, PhD  
Scientist, Gryphon Scientific, LLC**

Dr. Mark Kazmierczak is a molecular biologist with expertise in performing risk assessments to support government decision making on issues of biosecurity, public health, and biodefense. Since joining Gryphon Scientific in 2010, he has led analyses that inform U.S. biosecurity policy at the highest levels and has designed and performed risk assessments to protect our nation's health and prosperity. His prominent work has been used to assess biocontainment practices for the National Bio and Agro-Defense Facility; to support purchasing decisions for the drugs and medical supplies in the Strategic National Stockpile; and to inform dual-use research policy at the NIH. Dr. Kazmierczak authored the February 2019 report *China's Biotechnology Development: The Role of US and Other Foreign Engagement*, prepared for the U.S.-China Economic and Security Review Commission. Through his expertise in risk assessment and in-depth understanding of biotechnology and its applications, Dr. Kazmierczak has become a leader in the analysis of prominent biosafety and biosecurity issues for the U.S. Government. Dr. Kazmierczak holds a Ph.D. in microbiology from Cornell University.

### **Questions for Panelist**

- What health products or services are Chinese firms providing in the United States, and how have these products/services changed over the last 5 years?
- What genomic research have Chinese entities provided to U.S. companies or individuals? What concerns, if any, should policy makers have regarding these activities?
- Do Chinese government regulations managing the production and export of health products and medicines sufficiently address potential public health concerns?
- What are the trends and implications of Chinese investment in the U.S. health, biotech, and pharmaceutical industries?
- How do Chinese investments, cooperative research ventures, intellectual property theft, and other activities in health and pharmaceutical industries advance China's interests, and do they present a threat to U.S. economic or national security interests?
- What are Chinese biotechnology firms' activities in the United States, and do these activities pose data privacy or other national security risks?
- What specific sourcing vulnerabilities exist for private U.S. medical facilities, patients, and consumers vis-à-vis Chinese medical and biotech companies?
- Is the U.S. government adequately equipped to address risks to U.S. public health or national security posed by China's role in medical, pharmaceutical, and biotech supply chains?
- The Commission is mandated to make policy recommendations to Congress based on its hearings and other research. What are your recommendations for Congressional action related to the topic of your testimony?